Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma

Current Medical Research and Opinion
Steven R ArikianSaad Z Usmani

Abstract

Few studies have addressed the cost patterns of patients with multiple myeloma (MM) before and after first relapse. This US claims analysis evaluated, from a US health plan perspective, patterns of total direct costs of care from treatment initiation to progression for patients with MM treated with novel agents, using time to next therapy (TTNT) as a proxy measure for progression. A retrospective study was conducted using a large US claims database, evaluating patients with claims for MM between 2006 and 2013. Patients with claims for stem cell transplant (SCT) were excluded. The analysis focused on patients receiving lenalidomide (LEN) or bortezomib (BORT) based treatment, for whom complete claim history was available through initiation of subsequent treatment. Average patient monthly direct costs were determined, including medical and pharmacy costs, and total cost patterns over quarterly time periods were calculated. The study population comprised 2843 patients with newly diagnosed MM (NDMM) and 1361 with relapsed MM. Total monthly cost for patients with NDMM declined steadily, from $15,734 initially to $5082 at 18+ months after therapy. Upon initiation of second-line therapy, total monthly costs rose to $13,876 and declined...Continue Reading

References

Jul 29, 2006·Blood·Michel AttalUNKNOWN Inter-Groupe Francophone du Myélome (IFM)
Feb 13, 2010·European Journal of Cancer Care·D KolevaL Garattini
Jan 25, 2012·Blood·Heinz LudwigUNKNOWN International Myeloma Working Group
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
May 15, 2012·Leukemia Research·Yuki KagoyaMineo Kurokawa
Nov 7, 2012·Journal of Clinical Pharmacy and Therapeutics·J G GaultneyC A Uyl-de Groot
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jesús F San MiguelPaul G Richardson
Jan 10, 2013·The Oncologist·Jennifer G Gaultney, Carin A Uyl-de Groot
Jan 15, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboRobert Z Orlowski
Sep 4, 2014·The New England Journal of Medicine·Antonio PalumboMichele Cavo
Sep 4, 2014·The New England Journal of Medicine·Lotfi BenboubkerUNKNOWN FIRST Trial Team

❮ Previous
Next ❯

Citations

Feb 22, 2017·Cancer·B Douglas SmithBrian G M Durie
Jul 25, 2017·Journal of Managed Care & Specialty Pharmacy·Ying ChenXianglin L Du
Dec 27, 2017·Journal of Medical Economics·Sebastian Gonzalez-McQuireLeah Fink
Oct 19, 2019·Expert Review of Hematology·Tianqi XuGuangxun Gao
Aug 8, 2019·Leukemia & Lymphoma·May HagiwaraRafael Fonseca
Jul 7, 2017·Oncology and Therapy·Steve ScheySujith Dhanasiri
Mar 28, 2019·Journal of Managed Care & Specialty Pharmacy·Sarah HollmannEric M Maiese
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Rafael Fonseca, Jennifer Hinkel
Oct 12, 2018·International Journal of Hematologic Oncology·John AshcroftChloe Middleton
Feb 23, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Joshua RichterDrishti Shah

❮ Previous
Next ❯